Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of JS1-1-01 in Healthy Subjects
NCT05656274Phase 1Completed
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Nov 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing JS1-1-01 with Placebo (2 arms). Primary endpoint: Safety and Tolerability at Day 11. Started Nov 2022; status: completed.
02
Drugs
JS1-1
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05656274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05656274.